Sarcomas are rare cancers of the bone, muscle, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues. EuroSARC is a European initiative to combat rare sarcomas that includes nine clinical trials. CSM supports two of the EuroSARC trials that focus on bone cancer.
LINES: Linsitinib in advanced Ewing Sarcoma
LINES is a multicentre international Phase II EuroSARC trial. It tests whether a dual IGF1/IR inhibitor, linsitinib, has an effect in relapsed and/or refractory Ewing sarcoma, a bone cancer. This trial is run by OCTO and is currently recruiting patients.
MEMOS: Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma
MEMOS is a Phase II EuroSARC trial. It tests whether a synthetic version of MDP called Mifamurtide is effective in relapsed and/or metastatic osteosarcoma patients. This trial is run by OCTO and is currently recruiting patients.